| 18th week of 2010 patent applcation highlights part 62 |
| Patent application number | Title | Published |
|---|
| 20100113524 | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety - The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R | 2010-05-06 |
| 20100113525 | PEST CONTROL COMPOSITION - Disclosed is a pest control composition comprising at least one pyripyropene derivative of formula (I) or agriculturally and horticulturally acceptable salt thereof and at least one other pest control agent as active ingredients. The combined use of the two ingredients can provide a better insecticidal effect. | 2010-05-06 |
| 20100113526 | Process for the Preparation of Esomeprazole Magnesium Dihydrate - A process for preparing Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium dihydrate, processes for preparing various intermediates useful in the preparation of Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium dihydrate and a novel polymorphic Form II of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole. | 2010-05-06 |
| 20100113527 | CRYSTALLINE FORMS OF DEXLANSOPRAZOLE - Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof. | 2010-05-06 |
| 20100113528 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS - The present invention provides compounds of formula (I) or salts thereof: | 2010-05-06 |
| 20100113529 | DOSAGE REGIMEN FOR COMT INHIBITORS - The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. | 2010-05-06 |
| 20100113530 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA - Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed. | 2010-05-06 |
| 20100113531 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R | 2010-05-06 |
| 20100113532 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): | 2010-05-06 |
| 20100113533 | Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide - The present invention relates to the polymorph II of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders. | 2010-05-06 |
| 20100113534 | Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same - A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1. | 2010-05-06 |
| 20100113535 | TREATMENT OF PRESBYOPIA WITH ALPHA- PICOLINIC ACID AND ITS ANALOGS - Compositions and methods for inhibiting the growth of lens epithelial cells are provided. The compositions provided include a chelating agent in an amount sufficient for inhibiting the growth of lens epithelial cells. The compositions and methods provided may also be used for the treatment of disorders of the eye, especially in the treatment of presbyopia. | 2010-05-06 |
| 20100113536 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES - The present invention relates to novel compounds of formula [I], wherein R | 2010-05-06 |
| 20100113537 | ANTIMICROBIAL FIBER AND ITS PRODUCTION METHOD, AND ANTIMICROBIAL FIBER PRODUCT COMPRISING THE ANTIMICROBIAL FIBER, ITS PRODUCTION METHOD AND REGENERATION METHOD - An antimicrobial fiber bearing an anionic functional group, and a method of producing it wherein at least a part of the anionic functional group forms a quaternary ammonium salt and at least another part thereof forms an antimicrobial metal salt. The quaternary ammonium salt is preferably a cetylpyridinium salt, and the antimicrobial metal salt is preferably a zinc salt. The fiber is preferably a carboxyalkylated cellulose fiber. An antimicrobial fiber product comprising the antimicrobial fiber. | 2010-05-06 |
| 20100113538 | N-HYDROXY-4- BENZAMIDINE 2 ETHANSULFONIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 ethansulfonic acid salt, a process for the preparation thereof, a pharmaceutical composition for preventing and treating osteoporosis, bone fractures or allergic inflammatory diseases, comprising the same, and an oral formulation for preventing and treating osteoporosis, bone fractures or allergic inflammatory diseases, comprising the same are described. | 2010-05-06 |
| 20100113539 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 2010-05-06 |
| 20100113540 | Azole and Thiazole Derivatives and Their Use - Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: wherein (i) R | 2010-05-06 |
| 20100113541 | CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen. | 2010-05-06 |
| 20100113542 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR - 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role. | 2010-05-06 |
| 20100113543 | Crystalline Complexes of Agriculturally Active Organic Compounds - The present invention relates to crystalline complexes comprising at least one agriculturally active organic compound A having at least one functional moiety which is capable as serving as a hydrogen acceptor in a hydrogen bond and thiophanate-methyl. | 2010-05-06 |
| 20100113544 | Suppressant for cerebral infarction attributed to long-time ischemia - An object of the present invention is to provide a cerebral infarction suppressant which is effective for brain tissue necrosis after long-time ischemia as in actual cerebral infarction and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in that histidine is contained and the cerebral infarction is attributed to long-time ischemia. | 2010-05-06 |
| 20100113545 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - Compounds of formula (I) or a salt thereof are provided: | 2010-05-06 |
| 20100113546 | Imidazol-4-one and Imidazole-4-thione Compounds - Imidazol-4-one or imidazole-4-thione compounds of formula (I): | 2010-05-06 |
| 20100113547 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS - Novel compounds are disclosed that have a Formula represented by the following: | 2010-05-06 |
| 20100113548 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to antagonists of the human bitter-taste receptors hTAS2R38. The invention also relates to methods for identifying further molecules that suppress hTAS2R38 mediated bitter taste transduction or bitter taste response and uses thereof. | 2010-05-06 |
| 20100113549 | PYRROLIDINE COMPOUNDS - The present invention relates to a process for the preparation of a pyrrolidone compound of the formula (I): where R | 2010-05-06 |
| 20100113550 | New Crystal Forms - Polymorphs of (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione hydrochloride and methods of their preparation. | 2010-05-06 |
| 20100113551 | COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES - The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, novel process intermediates and methods for making the novel process intermediates. | 2010-05-06 |
| 20100113552 | FUNGICIDAL COMPOSITION - A composition comprising (i) a compound of Formula (I), wherein R | 2010-05-06 |
| 20100113553 | METHODS OF USING PROTEINACIOUS CHANNELS TO IDENTIFY PHARMACEUTICAL TREATMENTS AND RISKS, AND TREATMENTS RESULTING THEREFROM - Methods and therapeutic strategies utilizing proteinacious channels in lipid membranes of mammalian cells. The methods entail administering a pharmaceutical to a lipid membrane of a mammalian cell, and then determining the effect of the pharmaceutical on the electrophysiology of at least one vascular proteinacious channel of the lipid membrane, wherein the vascular proteinacious channel is a vascular Kv7 potassium channel and/or a vascular L-type calcium channel. The method can be used to identify pharmaceuticals that may be used to treat hypertension and/or vasospastic conditions, or to perform drug screening to assess potential cardiovascular risk of pharmaceuticals. | 2010-05-06 |
| 20100113554 | MANUFACTURE AND PRODUCTS THEREOF OF PHOTOSENSITIZING NANOMATERIALS AND THEIR USE IN PHOTODYNAMIC TREATMENT - A method for the manufacture of a photosensitizing nanomaterial ( | 2010-05-06 |
| 20100113555 | Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2010-05-06 |
| 20100113556 | NOVEL CRYSTAL FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES - The present invention provides novel crystalline forms D1 and D2 of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D | 2010-05-06 |
| 20100113557 | METHOD FOR PREVENTION OF TUMOR - The present invention provides a method for inhibiting a tumor, which comprises suppressing the expression of HERC2. In one embodiment of the present invention, the suppression of HERC2 is induced by the expression of BRCA1. | 2010-05-06 |
| 20100113558 | COMPOUNDS AND METHODS - A small nucleic acid molecule that down-regulates expression of Wrap53 gene via RNA interference (RNAi), wherein at least one strand of said small nucleic acid molecule is about 15 to about 30 nucleotides in length; and wherein at least one strand of said small nucleic acid molecule comprises a nucleotide sequence having sufficient complementarity to an RNA of said Wrap53 gene for the small nucleic acid molecule to direct cleavage of said RNA via RNA interference, for use as a medicament. | 2010-05-06 |
| 20100113559 | Chitosan Based Polymer Conjugate and a Method for Producing the Same - The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine. | 2010-05-06 |
| 20100113560 | COMPOSITIONS AND METHODS FOR TREATING HEMATOPOIETIC MALIGNANCIES - Described herein are compositions and methods for the prevention and treatment of hematopoietic malignancies. The compositions are miRNAs and associated nucleic acids. | 2010-05-06 |
| 20100113561 | MICRORNA MOLECULES | 2010-05-06 |
| 20100113562 | THERAPEUTIC TARGETS AND MOLECULES - The invention provides methods and compositions for treating or preventing inflammation or an inflammatory condition in a subject, comprising administering to the subject an effective amount of at least one antagonist of one or more miRNA upregulated in inflammatory disease conditions and response to allergen challenge. The invention also provides methods for diagnosing inflammatory conditions based on miRNA expression profile signatures. | 2010-05-06 |
| 20100113563 | Method for Treating Pain with a Calmodulin Inhibitor - The present invention relates to the use of Ca | 2010-05-06 |
| 20100113564 | RNA Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) - This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of interleukin and/or interleukin receptor genes. | 2010-05-06 |
| 20100113565 | IMMUNOSTIMULATORY COMBINATIONS AND METHODS - The invention provides immunostimulatory compositions and methods of enhancing TLR8-mediated biological activity. Generally, the immunostimulatory compositions include a TLR8 agonist and an immunostimulatory oligonucleotide in an amount effective to enhance TLR8-mediated biological activity. The invention also provides methods of inducing TLR8-mediated biological activity in immune cells. Generally, the methods include contacting immune cells with an immunostimulatory composition that includes a TLR8 agonist and an immunostimulatory oligonucleotide in an amount effective to enhance TLR8-mediated biological activity. In some cases, the immunostimulatory composition provides a synergistic enhancement of TLR8-mediated biological activity. | 2010-05-06 |
| 20100113566 | NUCLEIC ACID FOR TREATMENT OR PREVENTION OF IMMUNODEFICIENCY VIRUS INFECTION - A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection. | 2010-05-06 |
| 20100113567 | Recombinant VSV For The Treatment of Tumor Cells - The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual. | 2010-05-06 |
| 20100113568 | METHODS FOR BINDING LEWIS Y ANTIGEN - A method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of nucleotide sequence encoding N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues; and a method of detecting cancer cells, Gram-negative bacteria or LPS which over-express the Lewis Y antigen in a sample from a subject. | 2010-05-06 |
| 20100113569 | ISOLATED DNA FRAGMENT OF THE HUMAN A33 PROMOTER AND ITS USE TO CONTROL THE EXPRESSION OF A HETEROLOGOUS GENE IN TUMOR CELLS - An isolated DNA sequence that corresponds to a region of the human A33 gene promoter from base pair −105 to base pair +307, able to control the expression of a heterologous gene of interest, that may be used in conjunction with any other regulatory sequence, including sequences responsive to stress such as radiation, hypoxia and free radical formation. Constructs and viral vectors for recombinant DNA expression are provided, which include this sequence of human A33 gene promoter and, operably linked thereto, at least one heterologous gene. The regulatory sequence(s) control(s) the expression of at least one heterologous gene in cells including colorectal cancer cells. Pharmaceutical compositions and methods for treating colorectal cancer are also described. | 2010-05-06 |
| 20100113570 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION - Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein. | 2010-05-06 |
| 20100113571 | COMPOUNDS HAVING ANTI-ADHESIVE EFFECTS ON CANCER CELLS - Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3′->P5′ thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells. | 2010-05-06 |
| 20100113572 | PHOTOREACTIVE RU (II) COMPLEXES ANCHORED ON OLIGONUCLEOTIDES, METHOD FOR OBTAINING THEM AND USE THEREOF - Photoreactive Ru (II) complexes are anchored on a G-containing oligonucleotide, e.g. compound 1. The method for obtaining them and their use, includes targeting specific nucleotide sequences that become photocrosslinked to the photoreactive Ru (II) complex anchored to the G-containing oligonucleotide. | 2010-05-06 |
| 20100113573 | MODULATION OF HIF1 BETA EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided. | 2010-05-06 |
| 20100113574 | POLYNUCLEOTIDES FOR ENHANCING EXPRESSION OF A POLYNUCLEOTIDE OF INTEREST - The present invention relates to polynucleotides comprising a first nucleic acid sequence for a chromatin element, which is capable of enhancing expression, and at least one second nucleic acid sequence comprising a curved origin motif. Furthermore, the invention relates to a host cell, a non-human transgenic organism, a vector and a kit comprising the aforementioned polynucleotide. Moreover, the invention relates to methods for expressing a polynucleotide of interest. | 2010-05-06 |
| 20100113575 | METHOD FOR DETECTING AUTOPROCESSED, SECRETED PCSK9 - The present invention provides a method for detecting autoprocessed, secreted PCSK9, a protein involved in cholesterol homeostasis, and for effectively identifying compounds that inhibit autocleavage and secretion from cells. The disclosed method involves the insertion of an epitope tag into a PCSK9 expression construct immediately C-terminal to the pro domain ending at an amino acid residue corresponding to Q152 of human PCSK9. Upon autoprocessing, the epitope tag is exposed and capable of recognition by anti-epitope antibodies or other suitable identification system, allowing for the selective and exclusive identification and/or quantification of processed PCSK9. The present disclosure thus advances the goal of providing enabling technology to the art for the effective identification of therapeutics effective in combating coronary heart disease. | 2010-05-06 |
| 20100113576 | Device and Method for Processing or Treating Surfaces By Means of A Dry Ice Granulate - The invention relates to an apparatus for surface processing or surface treatment by means of dry ice granulate, with a reservoir for receiving a dry ice medium, in particular dry ice pellets, an inlet for the feed of a propellant medium, an outlet for the supply of a mixture of propellant medium and dry ice granulate to a blast gun, and an outflow chamber lying therebetween, there being arranged in the path between the reservoir and the outflow chamber a grinding mechanism, which is formed so as to comminute the dry ice medium to dry ice granulate with a particle size in a prescribed range, and a transport roll ( | 2010-05-06 |
| 20100113577 | ISOLATED NUCLEIC ACID MOLECULES CORRESPONDING TO MICRO RNA 145 (MIRNA-145) AND THEIR USE IN TREATING COLON CANCER - Provided herein are isolated nucleic acid molecule corresponding to miR145 that are useful in treating colon cancer. The disclosed miR145 nucleic acids specifically bind the 3′ UTR within endogenous IRS-I such as to suppress or inhibit colon cell proliferation. | 2010-05-06 |
| 20100113578 | Prevention of and countermeasures against mitochondrial disease - The present invention relates to an agent containing L-arginine, 0.2 to 20 parts by weight of L-ascorbic acid per 1 part by weight of L-arginine, and, if desired, at least one selected from the group consisting of ribonucleic acids, ribonucleotides and ribonucleosides. The agent can treat mitochondrial disease which shows a variety of symptoms caused by dysfunction of mitochondria in cells. L-arginine contained in the agent for treating mitochondrial disease of the present invention increases an NO radical level to thereby dilate the arteries. L-ascorbic acid serves to mitigate a harsh taste and acrid feeling accompanied with the intake of L-arginine and eliminate excessive NO radicals. | 2010-05-06 |
| 20100113579 | PRODRUGS OF EXCITATORY AMINO ACIDS - This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. | 2010-05-06 |
| 20100113580 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising bupropion, metformin, orlistat, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and orlistat. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 2010-05-06 |
| 20100113581 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising diethylpropion, metformin, orlistat, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of diethylpropion, metformin, and orlistat. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 2010-05-06 |
| 20100113582 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS - Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases. | 2010-05-06 |
| 20100113583 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising bupropion, metformin, topiramate, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and topiramate. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 2010-05-06 |
| 20100113584 | NOVEL USE OF (-)-EPIGALLOCATECHIN GALLATE - Use of (−)-epigallocatechin gallate and/or one or more of its derivatives for increasing the desire, willingness and/or motivation of animals (including humans), especially mammals, to exercise, to perform and/or to run, especially to perform endurance exercise and furthermore to accelerate training success. | 2010-05-06 |
| 20100113585 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Compounds of formulas I-IV: (I), (II), (III) (IV), wherein: R | 2010-05-06 |
| 20100113586 | PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF MENOPAUSAL SYMPTOMS - Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal. | 2010-05-06 |
| 20100113587 | Abscissic acid and derivatives thereof for the treatment of diseases - The present invention relates generally to the fields of molecular biology and pharmacology. More particularly, it concerns the use of abscissic acid to treat various diseases, including neurodegenerative diseases and neuromuscular diseases. | 2010-05-06 |
| 20100113588 | Composition and Methods for the Protection of Hair From Treated Pool Water - Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed. | 2010-05-06 |
| 20100113589 | Deuterated darunavir - This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir. | 2010-05-06 |
| 20100113590 | ADAM INHIBITOR - Disclosed is an ADAM inhibitor which enables to prevent or improve conditions caused by increase in ADAM activity. Specifically disclosed is an ascorbic acid derivative represented by the general formula (1) below or a salt thereof. [chemical formula 1] (1), wherein R represents a linear or branched alkyl group having 1 to 22 carbon atoms. | 2010-05-06 |
| 20100113591 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 2010-05-06 |
| 20100113592 | UNSYMMETRICAL AROMATIC ETHER DIACIDS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to compounds and compositions of formula I, which are unsymmetrical aromatic ether diacids, and polymers formed from the same. | 2010-05-06 |
| 20100113593 | TOPICAL FUNGICIDAL AGENTS FOR TREATING NAIL DISORDERS - The invention relates to water-free, topically applicable agents for treating, nail problems caused by mycoses, and for nail care, said agents containing at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid or citric acid and physiologically compatible auxiliary substances. The agents according to the invention can also be used in veterinary medicine for treating fungal infections of hooves, claws and talons of pets, working animals and wild animals in captivity. | 2010-05-06 |
| 20100113594 | PESTICIDAL COMPOSITION AND METHOD FOR CONTROLLING HARMFUL INSECTS - A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150 C or higher and a 95%-distillation temperature of 300 C or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate esters having 12 to 20 carbon atoms, (ii) dialkyl dicarboxylate esters having 12 to 20 carbon atoms, and (iii) trialkyl acetylcitrate esters having 12 to 20 carbon atoms; has an excellent pesticidal activity. | 2010-05-06 |
| 20100113595 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 2010-05-06 |
| 20100113596 | Method for inhibiting liver fibrosis via retinoic acid derivative - Transforming growth factor-beta1 (TGF-β1) mediates expression of collagen 1A2 (Col 1A2) gene via a synergistic cooperation between Smad2/Smad3 and Sp1, both act on the Col 1A2 gene promoter. The present invention discloses a method for inhibiting liver fibrosis via a retinoic acid derivative primarily extracted from the mycelia of | 2010-05-06 |
| 20100113597 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OF PROGRESS OF INTESTINAL CONSTRICTION ASSOCIATED WITH CROHN'S DISEASE - The present invention provides an oral pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease. That is, the present invention relates to a pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease which comprises as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid (generic name: tranilast) or a pharmaceutically acceptable salt thereof. The present invention can provide a pharmaceutical composition useful as an agent for inhibiting the progression of intestinal stricture associated with Crohn's disease for medical therapy. | 2010-05-06 |
| 20100113598 | HIGH DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE COMPULSIVE SPECTRUM DISORDERS - The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment. | 2010-05-06 |
| 20100113599 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS - The present invention relates to the use of at least one long-chain optionally-substituted amphipatic carboxylates (known as MEDICA drugs) or any salt, ester or amid thereof or any combination or mixture thereof, for the treatment and prevention of immune-related disorders, particularly, inflammatory conditions. More specifically, the invention relates to particular analogs of these MEDICA drugs, the 3,3,14,14 tetramethyl-hexadecanedioic acid (M16ββ), 4,4,15,15 tetramethyl-octadecanedioic acid (M18γγ) and 2,2,15,15-tetramethyl-hexadecanedioic acid (M16αα). The invention further provides methods, oral compositions and kits for the treatment and prevention of immune-related disorders using these MEDICA drugs. The disease is any one of multiple sclerosis, neurodegenerative disease, an atherosclerotic disease, inflammatory bowel diseases, arthritis. Wherein said atheroslerotic disease is any one of cardiovascular disease, cerebrovascular disease and peripheral vessel disease, and a malignant proliferative disorder line carcinoma, myeloma, leukemia, lymphoma, sarcoma and melanoma. | 2010-05-06 |
| 20100113600 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND - A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer. | 2010-05-06 |
| 20100113601 | METHOD FOR DECREASING SEBUM PRODUCTION - The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin. | 2010-05-06 |
| 20100113602 | USE OF HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM METASTASES - Disclosed is a method of treating a localized carcinoma central nervous system (CNS) metastasis of extra-CNS origin, the method comprising systemically administering an effective amount of a histone deacetylase (HDAC) inhibitor (HDI) to a subject in need of treatment for the localized carcinoma CNS metastasis of extra-CNS origin. The HDI can be any HDI capable of crossing the blood-brain barrier (BBB) such as vorinostat. The localized carcinoma CNS metastasis of extra-CNS origin can be a localized carcinoma brain metastasis. The localized carcinoma brain metastasis can originate in the breast. The CNS metastasis treated can be a micrometastasis, a brain tumor, or an intervening stage of brain cancer. | 2010-05-06 |
| 20100113603 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising bupropion, metformin, phentermine, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and phentermine. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 2010-05-06 |
| 20100113604 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising metformin, diethylpropion, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of metformin and diethylpropion. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 2010-05-06 |
| 20100113605 | METHODS, COMPOSITIONS AND USES THEREOF - The invention relates to a method for identifying a candidate compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission in the central nervous system, the method comprising the following steps: (a) providing a compound to be tested; (b) testing the ability of the compound to bind to the cocaine-binding site of a monoamine reuptake transporter; and (c) testing the ability of the compound to modulate the inward or outward transport of monoamine neurotransmitters via the monoamine reuptake transporter, wherein the test compound is identified as a candidate compound for treating a disorder or condition associated’ with dysfunction of monoamine neurotransmission if it is able to bind to the cocaine-binding site of the monoamine reuptake transporter and modulate its activity. The invention further relates to compounds identified using the method of the invention, and uses, compositions and medicaments thereof. | 2010-05-06 |
| 20100113606 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR - The present invention relates to new aminopropanol modulators of beta-1 adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-06 |
| 20100113607 | Pharmaceutical Compositions - A method for the topical treatment of nail diseases, e.g. onychomycosis, after preparation of the infected nail with a laser beam. | 2010-05-06 |
| 20100113608 | Tryptase Enzyme Inhibiting Aminothiophenols - Disclosed herein are novel compounds and pharmaceutical compositions comprising these compounds. In some embodiments, the compounds are inhibitors of the tryptase enzyme and are useful for treating allergic rhinitis, asthma, vascular injury (e.g., restenosis and atherosclerosis), inflammatory bowel disease, arthritis, psoriasis, anaphylaxis, wounds, infections, and other allergy and inflammatory related diseases. | 2010-05-06 |
| 20100113609 | METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a protease inhibitor. A pharmaceutical composition for preventing malaria infection including a protease inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by inhibiting circumsporozoite protein processing or by inhibiting a protease of a sporozoite. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing. | 2010-05-06 |
| 20100113610 | METHODS FOR CONTROLLING INFLAMMATORY AND IMMUNOLOGICAL DISEASES - The present invention provides methods for generating mucosal tissue homing immunosuppressive T-cells comprising treating naïve T-cells with retinoids and/or retinoid agonists. Methods are also provided for treating a mammal having an inflammatory or immunological disease by administering a therapeutically effective dose of retinoids and/or retinoid agonists. Additional methods are also provided for boosting the immune system of a mammal by inhibiting the generation of immunosuppressive T-cells by administering a therapeutically effective dose of a retinoid receptor antagonist to the mammal. | 2010-05-06 |
| 20100113611 | NOVEL USE OF HYDROXYTYROSOL - The invention relates to the use of hydroxytyrosol for inducing or enhancing cartilage repair or cartilage regeneration. Furthermore, the invention relates to nutraceutical and pharmaceutical compositions comprising hydroxytyrosol for regeneration and repair of cartilage injuries in joints, in particular of traumatic cartilage injuries. | 2010-05-06 |
| 20100113612 | NOVEL USE OF HYDROXYTYROSOL AND OLIVE EXTRACTS/CONCENTRATE CONTAINING IT - The present invention is directed to the use of (a composition comprising) hydroxytyrosol as life prolonging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is preferably administered orally to animals. The present invention is further directed to a life prolonging method. “Life prolonging” meaning in the context of the present invention: reducing the risk to die at a certain age compared to untreated; increasing the chance to live longer (longevity), i.e. increasing the average life expectancy compared to untreated; and/or extending the lifetime independent of medical care. | 2010-05-06 |
| 20100113613 | CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION - The invention provides formulations, dosage forms, and treatments comprising cyclohexane polyalcohol compounds that provide beneficial pharmacokinetic profiles in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. In aspects of the invention, a dosage form is provided comprising an amount of a cyclohexane polyalcohol compound suitable for administration to a subject to provide a therapeutically effective concentration of the compound in plasma, brain and/or cerebral spinal fluid and a pharmaceutically acceptable carrier, diluent or excipient. The formulation can be administered in a dose of 500, 1000, 2000, 3500, 5000 or 7000 mg of cyclohexane polyalcohol compound to achieve a mean plasma concentration profile having a mean AUC | 2010-05-06 |
| 20100113614 | Compositions and Methods for delivery of frozen particle adhesives - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
| 20100113615 | Compositions and methods for delivery of frozen particle adhesives - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
| 20100113616 | INHIBITION OF DISCOLORATION BY WASHING AND CLEANING AGENTS AND/OR COSMETIC AGENTS - Method of inhibiting discoloration in agents by incorporating iodide salt(s), preferably calcium, potassium and/or sodium iodides into the formulation of those agents. The method is particularly suited for agents comprising vanillin and/or vanillin derivatives, wherein vanillin and/or vanillin derivatives are components of a fragrance mixture and the agents are washing and cleaning agents or cosmetics agents. | 2010-05-06 |
| 20100113617 | METHOD FOR IMPLEMENTING ACTIVE INGREDIENTS IN ORDER TO PROTECT THEM AND OPTIMIZE THEIR DELIVERY METHOD - The invention pertains to a new method for formulating pharmaceutical active ingredients in such a way as to protect them when ingested orally, and to allow for the controlling of the release of the active ingredient in the intestine. It relies upon the use of thickening acrylic emulsions with a pH greater than 5, containing hydrophobic groups, in order to encapsulate the pharmaceutical active ingredients for the purpose of encouraging their passage through the gastrointestinal barrier, while controlling the release kinetics of said active ingredients. | 2010-05-06 |
| 20100113618 | Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same - The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with a hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system. | 2010-05-06 |
| 20100113619 | HIGH-AMYLOSE SODIUM CARBOXYMETHYL STARCH SUSTAINED RELEASE EXCIPIENT AND PROCESS FOR PREPARING THE SAME - A process for obtaining a spray-dried high amylose sodium carboxymethyl starch comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, is provided. The process comprises providing an amorphous pregelatinized high amylose sodium carboxymethyl starch (HASCA); dispersing the amorphous pregelatinized HASCA in a solution comprising water and at least one first pharmaceutically acceptable organic solvent miscible with water and suitable for spray-drying; and spray-drying the dispersion to obtain the spray-dried HASCA comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, in the form of a powder. Also provided is a spray-dried HASCA sustained-release excipient. This excipient is useful for preparing a tablet for the sustained-release of at least one drug. | 2010-05-06 |
| 20100113620 | ENTERIC PHARMACEUTICAL CAPSULES - This invention pertains generally to the field of hard enteric capsules, and more particularly, to capsules consisting of (a) a film-forming, water-soluble polymer; (b) an acid-insoluble polymer; (c) a gelatinising agent; (d) an auxiliary for gelation; (e) at least one plasticiser; (f) minor ingredients, including, optionally, a colouring agent and a flavouring agent; and the balance of the composition being water. The present invention also pertains to the use of the capsule in the delivery of active pharmaceutical ingredients or dietary supplements and methods for producing hard enteric capsules. | 2010-05-06 |
| 20100113621 | WATER IN OIL (W/O) EMULSION FORMED BY USING REVERSE VESICLE - A water-in-oil (W/O) emulsion which is stable even with a high water content is provided. The water-in-oil (W/O) emulsion is obtained by a three-phase emulsification using a reverse vesicle of an amphiphilic compound as an emulsifier. As the amphiphilic compound, a sucrose fatty acid ester is preferable, and a sucrose fatty acid ester with an HLB value of 6-12 is more preferable. The reverse vesicle can be prepared by mixing an amphiphilic compound with a non-polar solvent. The water-in-oil (W/O) emulsion can be formed by using the prepared mixture containing the reverse vesicle as an oil phase and adding water thereto for emulsification. As the non-polar solvent, an alicyclic hydrocarbon solvent such as cyclohexane is preferable. The reverse vesicle preferably has a particle diameter of not more than 1 μm. | 2010-05-06 |
| 20100113622 | INTEGRATED MULTI-STEP SOLID/LIQUID SEPARATION SYSTEM FOR FISCHER-TROPSCH PROCESSES - A system for separating liquids from solids comprising an immobilization unit comprising an immobilization vessel containing a bed of magnetizable material and a magnet configured to produce a magnetic field within the immobilization vessel, wherein the immobilization vessel further comprises an immobilization vessel outlet and an immobilization vessel inlet for a fluid comprising liquid and metal-containing particles. A method for separating solid particles from liquid by introducing a fluid comprising liquid and a first concentration of solid particles into an immobilization unit comprising an immobilization vessel and at least one magnet configured to produce high density magnetic flux lines within the immobilization vessel and/or a high field gradient at or near the surface of the magnetizable material when powered, wherein the immobilization vessel contains therein a bed of magnetizable material; and removing from the immobilization unit a product having a second particle concentration less than the first particle concentration. | 2010-05-06 |
| 20100113623 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF SYNTHETIC HYDROCARBON COMPOUNDS - A process and system for producing hydrocarbon compounds or fuels that recycle products of hydrocarbon compound combustion—carbon dioxide or carbon monoxide, or both, and water. The energy for recycling is electricity derived from preferably not fossil based fuels, like from nuclear fuels or from renewable energy. The process comprises electrolysing water, and then using hydrogen to reduce externally supplied carbon dioxide to carbon monoxide, then using so produced carbon monoxide together with any externally supplied carbon monoxide and hydrogen in Fischer-Tropsch reactors, with upstream upgrading to desired specification fuels—for example, gasoline, jet fuel, kerosene, diesel fuel, and others. Energy released in some of these processes is used by other processes. Using adiabatic temperature changes and isothermal pressure changes for gas processing and separation, large amounts of required energy are internally recycled using electric and heat distribution lines. Phase conversion of working fluid is used in heat distribution lines for increased energy efficiency. The resulting use of electric energy is less than 1.4 times the amount of the high heating value of combustion of so produced hydrocarbon compounds when carbon dioxide is converted to carbon monoxide in the invention, and less than 0.84 when carbon monoxide is the source. | 2010-05-06 |
